Immunoglobulin M Response Post DBL2Β-PFEMP1 Recombinant Protein Injection in Wistar Rats: Study for Malaria Vaccine Development
DOI:
https://doi.org/10.15408/kauniyah.v19i2.44265Keywords:
DBL, Malaria, PfEMP1, Plasmodium falciparum, VaccineAbstract
Vaccination is vital in malaria prevention strategies. The DBL2β-PfEMP1 recombinant protein is a malaria vaccine candidate due to its essential role in severe pathogenesis. This study analyzed the IgM levels after DBL2β-PfEMP1 recombinant protein injection. This study used nineteen male Wistar rats, aged 2–3 months, and was divided into a control group, which was injected with NaCl 0.9%, and four treatment groups, which were injected with DBL2β-PfEMP1 protein in doses of 150 μg without adjuvant, and 150, 300, and 450 μg with adjuvant. Rats were injected subcutaneously twice at a 6-week interval. Blood samples were collected two weeks after injection. IgM was measured using the ELISA. There was an increasing trend in IgM levels after the DBL2β-PfEMP1 protein injection with a dose-dependent effect in the primary injection. The One-way ANOVA test showed a significant difference between groups (p = 0.037), and the post-hoc Bonferroni test showed a significant difference only between a control and treatment group of 450 μg + adjuvant (p= 0.046). A trend of increasing IgM in secondary injection was only observed in the 150 μg + adjuvant group, which is suggested as an optimum dose. Further analysis of other immune indicators is needed to draw a comprehensive immune response in developing a malaria vaccine candidate.
References
Bachmann, A., Bruske, E., Krumkamp, R., Turner, L., Wichers, J. S., Petter, M., Held, J., Duffy, M. F., Sim, B. K. L., Hoffman, S. L., Kremsner, P. G., Lell, B., Lavstsen, T., Frank, M., Mordmüller, B., & Tannich, E. (2019). Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression. PLOS Pathogens, 15(7), e1007906. https://doi.org/10.1371/journal.ppat.1007906
Blank, A., Fürle, K., Jäschke, A., Mikus, G., Lehmann, M., Hüsing, J., Heiss, K., Giese, T., Carter, D., Böhnlein, E., Lanzer, M., Haefeli, W. E., & Bujard, H. (2020). Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial. Npj Vaccines, 5(1). https://doi.org/10.1038/s41541-020-0160-2
Boonyaratanakornkit, J., & Taylor, J. J. (2019). Immunoglobulin M, more than just an early responder to malaria. In Immunology and cell biology, 97(9). https://doi.org/10.1111/imcb.12292
Boyle, M. J., Chan, J. A., Handayuni, I., Reiling, L., Feng, G., Hilton, A., Kurtovic, L., Oyong, D., Piera, K. A., Barber, B. E., William, T., Eisen, D. P., Minigo, G., Langer, C., Drew, D. R., De Labastida Rivera, F., Amante, F. H., Williams, T. N., Anstey, N. M., & Beeson, J. G. (2019). IgM in human immunity to Plasmodium falciparum malaria. J. S. McCarthy, 5(9). http://doi.org/ 10.1126/sciadv.aax4489
Datoo, M. S., Natama, M. H., Somé, A., Traoré, O., Rouamba, T., Bellamy, D., Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., Soma, R., Sawadogo, S., Sorgho, F., Derra, K., Rouamba, E., Orindi, B., Ramos Lopez, F., Flaxman, A., Cappuccini, F., … Tinto, H. (2021). Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. The Lancet, 397(10287), 1809–1818. https://doi.org/10.1016/S0140-6736(21)00943-0
El-Moamly, A. A., & El-Sweify, M. A. (2023). Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects. Tropical Medicine and Health, 51(1). https://doi.org/10.1186/s41182-023-00516-w
Gill, J., Singh, H., & Sharma, A. (2023). Profiles of global mutations in the human intercellular adhesion molecule-1 (ICAM-1) shed light on population-specific malaria susceptibility. BMC Genomics, 24(1). https://doi.org/10.1186/s12864-023-09846-9
Gong, S., & Ruprecht, R. M. (2020). Immunoglobulin M: An Ancient Antiviral Weapon – Rediscovered. Frontiers in Immunology, 11(1943). https://doi.org/10.3389/fimmu.2020.01943
Hammershaimb, E. A., & Berry, A. A. (2023). Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond. In Expert Review of Vaccines, 23(1), 49–52. https://doi.org/10.1080/14760584.2023.2292204
Hasanah, F. H., Sulistyaningsih, E., & Sawitri, W. D. (2020). The Expression of The PfEMP1-DBL2β Recombinant Protein of Plasmodium falciparum Welch, 1897 Isolated From Indonesia. Jurnal ILMU DASAR, 21(1), 67. https://doi.org/10.19184/jid.v21i1.10494
Jensen, A. R., Adams, Y., & Hviid, L. (2020). Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. Immunological Reviews, 293(1) 230–252. https://doi.org/10.1111/imr.12807
Ji, C., Shen, H., Su, C., Li, Y., Chen, S., Sharp, T. H., & Xiao, J. (2023). Plasmodium falciparum has evolved multiple mechanisms to hijack human immunoglobulin M. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-38320-z
Kurtovic, L., Atre, T., Feng, G., Wines, B. D., Chan, J. A., Boyle, M. J., Drew, D. R., Hogarth, P. M., Fowkes, F. J. I., Bergmann-Leitner, E. S., & Beeson, J. G. (2021). Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated with Protection in a Phase 1/2a Trial. Journal of Infectious Diseases, 224(7), 1128–1138. https://doi.org/10.1093/infdis/jiaa144
Lee, W. C., Russell, B., & Rénia, L. (2019). Sticking for a cause: The falciparum malaria parasites cytoadherence paradigm. Frontiers in Immunology, 10(1444). https://doi.org/10.3389/fimmu.2019.01444
López, C., Yepes-Pérez, Y., Hincapié-Escobar, N., Díaz-Arévalo, D., & Patarroyo, M. A. (2017). What is known about the immune response induced by Plasmodium vivax malaria vaccine candidates?. Frontiers in Immunology, 8(126). https://doi.org/10.3389/fimmu.2017.00126
Minassian, A. M., Silk, S. E., Barrett, J. R., Nielsen, C. M., Miura, K., Diouf, A., Loos, C., Fallon, J. K., Michell, A. R., White, M. T., Edwards, N. J., Poulton, I. D., Mitton, C. H., Payne, R. O., Marks, M., Maxwell-Scott, H., Querol-Rubiera, A., Bisnauthsing, K., Batra, R., … Draper, S. J. (2021). Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med, 2(6), 701-719.e19. https://doi.org/10.1016/j.medj.2021.03.014
Nindela, R. (2015). Merozoite Surface Protein-1 (MSP-1) dan Merozoite Surface Protein-2 (MSP-2) Plasmodium falciparum sebagai Kandidat Vaksin Malaria. MKS, 47(1).
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017). Malaria. Nature Reviews Disease Primers, 3(1), 17050. https://doi.org/10.1038/nrdp.2017.50
Pleass, R. J., Moore, S. C., Stevenson, L., & Hviid, L. (2016). Immunoglobulin M: Restrainer of Inflammation and Mediator of Immune Evasion by Plasmodium falciparum Malaria. Trends in Parasitology, 32(2), 108–119. https://doi.org/10.1016/j.pt.2015.09.007
Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology, 21(2) 83–100. https://doi.org/10.1038/s41577-020-00479-7
Rachmania, S., Sulistyaningsih, E., & Ratna Dewi, A. A. I. (2020). Recombinant DBL2β-PfEMP1 of the Indonesian Plasmodium falciparum induces immune responses in Wistar rats. Journal of Taibah University Medical Sciences, 16(3), 422–430. https://doi.org/10.1016/j.jtumed.2020.12.007
Riley, E. M., & Stewart, V. A. (2013). Immune mechanisms in malaria: new insights in vaccine development. Nature Medicine, 19(2), 168–178. https://doi.org/10.1038/nm.3083
Rogers, K. J., Vijay, R., & Butler, N. S. (2021). Anti-malarial humoral immunity: the long and short of it. Microbes and Infection, 23(4–5).https://doi.org/10.1016/j.micinf.2021.104807
Sebina, I., & Pepper, M. (2018). Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics. Current Opinion in Immunology, 51(46–54). https://doi.org/10.1016/j.coi.2018.02.001
Sulistyaningsih, E. (2020). Vaksin Malaria: Perkembangan Generasi Vaksin, Kandidat Protein Untuk Vaksin, Dan Tantangannya. UPT Penerbitan Universitas Jember.
Tessema, S. K., Utama, D., Chesnokov, O., Hodder, A. N., Lin, C. S., Abby Harrison, G. L., Jespersen, J. S., Petersen, B., Tavul, L., Siba, P., Kwiatkowski, D., Lavstsen, T., Hansen, D. S., Oleinikov, A. V, Mueller, I., Barry, A. E., Tessema, C. S., & Gla, H. (2018). Antibodies to Intercellular Adhesion Molecule 1-Binding Plasmodium falciparum Erythrocyte Membrane Protein 1-DBL Are Biomarkers of Protective Immunity to Malaria in a Cohort of Young Children from Papua New Guinea. American Society for Microbiology, 86(8). https://doi.org/10.1128/IAI
WHO. (2021). Full Evidence Report on the RTS,S/AS01 Malaria Vaccine. Malaria Policy Advisory Group Meeting, Geneva. https://www.nitag-resource.org/sites/default/files/2022-05/Full-evidence-report-on-the-rtss-as01-malaria-vaccine-2021.pdf
WHO. (2023). WHO guidelines for malaria. WHO Global Malaria Programme. Geneva. https://iris.who.int/bitstream/handle/10665/379635/B09146-eng.pdf?sequence=1
WHO. (2024). Malaria vaccine: WHO position paper. Weekly epidemiological record. https://iris.who.int/bitstream/handle/10665/376738/WER9919-eng-fre.pdf?sequence=2
Wiser, M. F. (2023). Knobs, Adhesion, and Severe Falciparum Malaria. Tropical Medicine and Infectious Disease, 8(7). https://doi.org/10.3390/tropicalmed8070353
